WSD0922


Catalog No. Size PriceQuantity
M17423-C Contact sales@xcessbio.com for quotation $100

Description

WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy.

Product information

CAS Number: 2226552-64-1

Molecular Weight: 442.43

Formula: C23H21F3N4O2

Chemical Name: 6-{[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy}-N-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine

Smiles: COC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3F)=C2C=C1O[C@@H]1CCN(C)CC1(F)F

InChiKey: RIHUDRGMCALEAK-HXUWFJFHSA-N

InChi: InChI=1S/C23H21F3N4O2/c1-4-14-6-5-7-16(21(14)24)29-22-15-10-19(18(31-3)11-17(15)27-13-28-22)32-20-8-9-30(2)12-23(20,25)26/h1,5-7,10-11,13,20H,8-9,12H2,2-3H3,(H,27,28,29)/t20-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

WSD0922 treatment results in tumor regression on cetuximab resistant PDX model of HNSCC. WSD0922 demonstrates remarkable tumor regression in 3 PDX models (platinum sensitive/insensitive/EGFRm+). WSD0922 is well tolerated in GLP tox at dose ~10x clinical equivalent dose.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed